VPTDF - Ventripoint Appoints Randy AuCoin to Board of Directors
(TheNewswire)
Toronto, Ontario – TheNewswire –December 20, 2021 - Ventripoint Diagnostics Ltd.(" Ventripoint " or the " Company "), (TSXV:VPT ) ; ( OTC:VPTDF) is pleased to announce that Randy AuCoin hasjoined the Ventripoint Board of Directors.
“We are thrilled to have Randy AuCoin join the Boardof Directors and utilize his extensive experience in the developmentand commercialization of medical ultrasound and electrophysiologydevices”, stated Dr. George Adams, Executive-Chairman ofVentripoint.
Since 2013, Randy AuCoin has been the CEO of Exact Imaging, which isthe world leader in high-frequency ultrasound applied to the earlydetection of prostate cancer. Randy has raised over $50 million ofventure capital, and has had progressively more senior roles inQuinton Electrophysiology Corporation, DICOMIT, VisualSonics Inc. andImagistx Inc. Randy is well versed in all aspects of a medicaldevice company from operations to sales and marketing to governance.
The Company will benefit from Randy’s deep sector expertise andconnections.
“I have watched Ventripoint for many years as theynavigated the complex process of bringing a new technology andproducts into clinical medical practice. I look forward to assistingthem to grow the adoption of the VMS+ family of novel products andbecoming the stand-of-care for cardiac ultrasound diagnostics,”commented Randy AuCoin.
The company is also announcing the resignation of PeterWeichler from the Board of Directors. Peter will continue to be aconsultant to the Company on Investor Relations matters. The Boardwishes to thank Peter for his service as a Director to the Company forthe last two years.
“I want to personally thank Peter for joining theBoard and allowing the Company to re-structure for the success it isnow enjoying,” stated, Dr. George Adams, Executive-Chairman ofVentripoint.
The Company has awarded Randy 500,000 options at anexercise price of $.40 with a term of 10 years and vesting annuallyover 5 years.
About Ventripoint DiagnosticsLtd.
Ventripoint has become anindustry leader in the application of AI (Artificial Intelligence) toechocardiography. Ventripoint's VMS products are powered by itsproprietary KBR technology, which is the result of a decade ofdevelopment and provides accurate volumetric cardiac measurementsequivalent to MRI. This affordable, gold-standard alternative allowscardiologists greater confidence in the management of their patients.Providing better care to patients serves as a springboard and basicstandard for all of Ventripoint's products that guide our futuredevelopments. In addition, VMS+ is versatile and can be used with allultrasound systems from any vendor supported by regulatory marketapprovals in the U.S., Europe and Canada.
For further information, pleasecontact:
Dr. George Adams
519-803-6937
Neither the TSX Venture Exchange nor its RegulationServices Provider (as that term is defined in the policies of the TSXVenture Exchange) accepts responsibility for the adequacy or accuracyof this news release.
Forward Looking Statements
This news release contains forward-looking statementsand forward-looking information within the meaning of applicablesecurities laws. The use of any of the words "expect","anticipate", "continue", "estimate","objective", "ongoing", "may","will", "project", "should","believe", "plans", "intends'' and similarexpressions are intended to identify forward-looking information orstatements. The forward-looking statements and information are basedon certain key expectations and assumptions made by the Company.Although the Company believes that the expectations and assumptions onwhich such forward-looking statements and information are based arereasonable, undue reliance should not be placed on the forward-lookingstatements and information because the Company can give no assurancethat they will prove to be correct.
Since forward-looking statements and informationaddress future events and conditions, by their very nature theyinvolve inherent risks and uncertainties. Actual results could differmaterially from those currently anticipated due to a number of factorsand risks. Factors which could materially affect such forward-lookinginformation are described in the risk factors in the Company's mostrecent annual management's discussion and analysis that is availableon the Company's profile on SEDAR at www.sedar.com. Readers arecautioned that the foregoing list of factors is not exhaustive. Theforward-looking statements included in this news release are expresslyqualified by this cautionary statement. The forward-looking statementsand information contained in this news release are made as of the datehereof and the Company undertakes no obligation to update publicly orrevise any forward-looking statements or information, whether as aresult of new information, future events or otherwise, unless sorequired by applicable securities laws.
Copyright (c) 2021 TheNewswire - All rights reserved.